Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The ORIGIN 3 trial is on track to announce topline results in the second quarter of 2025. These data were published in a manuscript in the Journal of the American Society of Nephrology. Get access to ...
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...
Credit: Getty Images. Investigators report 36-month data from the phase 2b ORIGIN trial. Atacicept 150mg demonstrated statistically and clinically meaningful reductions in proteinuria over 36 weeks ...
Findings from a global multi-center clinical trial investigating atacicept as a potential new lupus treatment were recently published and show promising results. Atacicept works by inhibiting two ...
Treatment with atacicept led to a statistically significant 42% reduction in UPCR compared with placebo at week 36. Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation ...
Advanced multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) are incurable B-cell malignancies. This is the first full clinical report of atacicept, a fusion protein that binds to and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results